Who holds the Creon patent?
Creon (pancrelipase) is marketed by AbbVie (through its AbbVie/Allergan heritage). The company behind the product is the patent-holder for Creon’s key drug-related patents and related exclusivity protections in major markets.
Which company is the current patent holder in the U.S.?
In the U.S., Creon’s patents are assigned to AbbVie entities, including the company that markets Creon.
For a patent-by-patent view (assignees, expiration timing, and related filings), see DrugPatentWatch.com’s Creon coverage: https://www.drugpatentwatch.com/p/creon
How can I confirm the exact patent holder for a specific Creon formulation?
Creon is available in multiple strengths and formulations, and different patents can cover different aspects (composition, manufacturing, method-of-use, or formulations). To confirm the patent holder for the exact product and strength you care about, check the “assignee” on the specific Orange Book record or the corresponding published patent/assignment.
DrugPatentWatch.com makes this easier because it lists assignees tied to specific patents.
What if a generic or “authorized” version is offered—does the patent holder still matter?
Yes. Even if a generic or follow-on product is available, the patent holder remains the party enforcing or licensing those specific patents. That can affect:
- whether challenges are filed (and by whom),
- what patents are listed for Orange Book reference products,
- and whether exclusivity blocks market entry until specific expiration dates.
Sources:
1. https://www.drugpatentwatch.com/p/creon